Tirzepatide Therapy for Weight Loss

Patient Selection and FDA-Approved Indications

• Weight loss medications are FDA-approved for patients with BMI ≥30 kg/m² without additional risk factors, or BMI ≥27 kg/m² with at least one weight-related comorbidity, such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea, according to the American Heart Association, as published in Circulation 1
• The American College of Cardiology recommends that patients with a BMI ≥30 kg/m² or those with a BMI ≥27 kg/m² and at least one weight-related comorbidity be considered for weight loss medication, as stated in a study published in Circulation and supported by Diabetes Care 1, 2

Monitoring and Titration

• The American Diabetes Association suggests assessing efficacy and safety monthly for the first 3 months, then at least every 3 months thereafter, as recommended in Diabetes Care 2
• Discontinue tirzepatide if less than 5% weight loss is achieved after 12 weeks at maintenance dose, as this predicts poor long-term response, according to the European Association for the Study of Diabetes, as published in Diabetes Care 2

Expected Outcomes

• Weight loss of 15-21% is achievable with tirzepatide at higher doses over 72 weeks, as reported in the European Heart Journal 3
• The European Society of Cardiology recommends monitoring improvements in blood pressure, lipids, and liver enzymes as secondary benefits of tirzepatide therapy, as stated in the European Heart Journal 3

Addressing Elevated Calcium Levels

• The European Society of Endocrinology suggests repeating calcium levels with ionized calcium and PTH to rule out primary hyperparathyroidism before starting tirzepatide, as recommended in the European Heart Journal 3
• Tirzepatide is not contraindicated with mild hypercalcemia, but underlying causes should be identified, according to the European Society of Endocrinology, as published in the European Heart Journal 3

Critical Pitfalls to Avoid

• The American Heart Association advises against prescribing tirzepatide as monotherapy, as it must be combined with lifestyle modification to meet FDA approval criteria and maximize efficacy, as stated in Circulation 1
• The American Diabetes Association recommends not continuing tirzepatide beyond 12 weeks at maintenance dose if less than 5% weight loss is achieved, as this represents treatment failure, according to Diabetes Care 2

Obesity Management with Medications

Indications for Weight Loss Medications

• The American College of Cardiology recommends that weight loss medications should only be used as part of a comprehensive treatment program, including diet, physical activity, and behavioral therapy, for patients with a BMI ≥30 kg/m² or BMI ≥27 kg/m² with obesity-related comorbidities 4, 5
• Weight loss medications are indicated for patients with a BMI ≥30 kg/m² without risk factors or BMI ≥27 kg/m² with obesity-related comorbidities, such as hypertension, dyslipidemia, coronary heart disease, type 2 diabetes, or obstructive sleep apnea 6, 7

Approved Weight Loss Medications

• Orlistat (Xenical) is a lipase inhibitor that reduces fat absorption, with a dose of 120 mg, 3 times a day with meals, and has side effects including abdominal pain, diarrhea, and reduced absorption of fat-soluble vitamins 4, 5, 8
• Phentermine/topiramate (Qsymia) is a combination of an appetite suppressant and an antiepileptic drug, which should not be used in patients with cardiovascular disease 4, 5
• Liraglutide 3.0 mg (Saxenda) is a GLP-1 receptor agonist that is particularly beneficial for patients with type 2 diabetes 4, 5

Monitoring and Evaluation

• The American Heart Association recommends evaluating the effectiveness and safety of weight loss medications monthly for the first 3 months, then at least every 3 months 4
• Medications should be discontinued if patients do not achieve a weight loss of at least 5% of initial body weight after 3 months of treatment or have safety/tolerability issues 5, 8

Medication Selection Based on Comorbidities

• For patients with cardiovascular disease, it is recommended to avoid sympathomimetic agents like phentermine and phentermine/topiramate, and instead choose safer options like lorcaserin and orlistat 4
• For patients with type 2 diabetes, it is recommended to prioritize anti-diabetic medications with weight loss effects, such as GLP-1 analogues (liraglutide) and metformin 5

Pharmacotherapy Treatment Options for Weight Loss

Patient Selection Criteria

• The American College of Cardiology and other guideline societies recommend initiating pharmacotherapy for patients with BMI ≥30 kg/m² without additional risk factors, or BMI ≥27 kg/m² with at least one weight-related comorbidity, such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea, with a strength of evidence level of high 9
• For Asian populations, lower BMI cutoffs apply, and pharmacotherapy should be considered at BMI >27 kg/m² or >25 kg/m² with complications, as Asian populations develop obesity-related complications at lower BMI levels, with a moderate level of evidence 9

First-Line Pharmacotherapy Options

• The Endocrine Society recommends GLP-1 receptor agonists, such as liraglutide 3.0 mg, as a first-line option for chronic weight management, particularly for patients with type 2 diabetes, with a high level of evidence 10
• The American Heart Association suggests that semaglutide 2.4 mg produces sustained mean weight reduction of 15-20%, with substantial cardiometabolic benefits beyond weight loss, and is currently approved in the United States and Europe, but not yet in Asia for obesity treatment, with a moderate to high level of evidence 9

Medication Selection Algorithm

• The Obesity Society recommends prioritizing GLP-1 receptor agonists, such as tirzepatide, semaglutide, or liraglutide, for patients with type 2 diabetes, due to their dual metabolic benefits, with a high level of evidence 10
• For patients with cardiovascular disease, the American College of Cardiology advises avoiding sympathomimetic agents, such as phentermine, and instead choosing GLP-1 agonists, bupropion/naltrexone, or orlistat, with a moderate level of evidence 9

Monitoring and Treatment Duration

• The National Institute of Health recommends evaluating patients monthly for the first 3 months for efficacy and safety, and assessing for obesity-related complications, such as hypertension, dyslipidemia, and sleep apnea, with a high level of evidence 9
• The Endocrine Society suggests continuing assessment at least every 3 months after the initial period, and monitoring blood pressure, lipids, and liver enzymes as secondary benefits, with a moderate level of evidence 9

Critical Pitfalls to Avoid

• The American Heart Association warns against using pharmacotherapy as monotherapy, and instead recommends combining it with lifestyle modification throughout treatment, with a high level of evidence 9
• The Obesity Society advises against continuing ineffective treatment beyond 12 weeks at maintenance dose if <5% weight loss is achieved, and instead recommends switching to an alternative medication, with a moderate level of evidence 9

Weight Loss Medications Beyond GLP-1 and GLP-2 Agonists

FDA-Approved Long-Term Weight Loss Medications

• For patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities, several non-GLP-1/GLP-2 medications are FDA-approved for chronic weight management as adjuncts to diet and exercise, according to the American Diabetes Association 11, 12, 13
• The American Diabetes Association recommends phentermine monotherapy for short-term use (≤12 weeks) and should not be considered for chronic weight management, with dosing at 15-30mg daily, taken approximately 2 hours after breakfast 11, 12

Critical Treatment Principles

• The American Diabetes Association suggests that all FDA-approved weight loss medications require concurrent implementation of reduced-calorie diet (500-kcal deficit) and minimum 150 minutes weekly of physical activity 11, 12, 13
• The American Diabetes Association recommends discontinuing medication if weight loss is <5% after 3 months at therapeutic dose, as this predicts poor long-term response 11, 12, 13
• The American Diabetes Association advises assessing efficacy and safety monthly for first 3 months, then at least quarterly, with early responders (≥5% weight loss at 3 months) continuing long-term treatment 12, 13

Concomitant Medication Management

• The American Diabetes Association recommends minimizing medications that promote weight gain whenever possible, considering alternatives for weight-promoting medications such as antipsychotics, tricyclic antidepressants, and glucocorticoids 12, 13
• For diabetes patients, the American Diabetes Association prioritizes glucose-lowering medications with weight loss or weight-neutral effects, such as metformin and SGLT2 inhibitors, and avoids or minimizes insulin secretagogues, thiazolidinediones, and insulin when possible 11, 13

Metabolic Surgery Consideration

• The American Diabetes Association recommends metabolic surgery for patients with BMI ≥40 kg/m² (≥37.5 kg/m² in Asian Americans) or BMI 35-39.9 kg/m² (32.5-37.4 kg/m² in Asian Americans) who fail to achieve durable weight loss with medications, and considers surgery for BMI 30-34.9 kg/m² (27.5-32.4 kg/m² in Asian Americans) if medical management fails 12, 13

Management of Severe Obesity (BMI > 60 kg/m²) When Injectable Anti‑Obesity Medications Are Denied

Pharmacotherapy Options

• Initiate oral anti‑obesity medication—either naltrexone‑bupropion or phentermine/topiramate—combined with intensive lifestyle modification, and refer for bariatric surgery because the patient’s BMI 62.8 exceeds the surgical threshold of 40 kg/m². [14][15]
• Phentermine/topiramate is an appropriate oral alternative for patients with BMI ≥ 30 kg/m² but should be avoided in the presence of cardiovascular disease. 14
• Orlistat (120 mg three times daily with meals) yields an average weight loss of roughly 2.9 kg after 12 months; gastrointestinal adverse effects often limit its tolerability. 15
• All oral anti‑obesity agents must be prescribed together with a reduced‑calorie diet (≈ 500 kcal/day deficit) and at least 150 minutes per week of moderate‑intensity physical activity. 14

Monitoring and Treatment Evaluation

• Assess efficacy and safety monthly for the first three months, then at least every three months thereafter. [14][16]
• Discontinue the medication if < 5 % weight loss is achieved after three months at the therapeutic dose, as this predicts a poor long‑term response. 14

Expected Outcomes of Oral Therapy

• Oral anti‑obesity drugs typically produce 5–10 % loss of initial body weight over 6–12 months. 15
• A 5–10 % weight reduction is associated with modest improvements in cardiovascular risk factors, including an average ≈ 3 mm Hg decrease in systolic blood pressure, plus favorable changes in lipids and glycemic control. 15

Bariatric Surgery Referral

• The patient meets established criteria for bariatric surgery (BMI > 40 kg/m²) and should be referred immediately to a high‑volume bariatric center. [14][15]
• Surgery is considered the definitive treatment for severe obesity; pharmacotherapy alone is insufficient for patients with BMI > 60 kg/m². [17][15]
• Bariatric surgery achieves greater weight loss than medication alone and reduces cardiovascular morbidity and mortality in this population. 15
• While awaiting surgery, initiating oral pharmacotherapy and lifestyle changes can promote pre‑operative weight loss and improve peri‑operative outcomes. 18
• Referral to high‑volume centers is essential because surgical mortality ranges from 0.3 % to 1.9 %, with a clear learning‑curve effect. 15

Lifestyle Modification Framework

• Physical activity: Walking constitutes moderate‑to‑vigorous intensity for severely obese individuals, utilizing 56–98 % of VO₂max compared with 35 % in normal‑weight persons. Begin with low‑intensity activity to avoid fatigue and musculoskeletal injury. 18
• Recommend 150–300 minutes/week of moderate activity (or 75–150 minutes/week of vigorous activity) plus resistance training 2–3 times weekly. 14
• Dietary approach: Implement a reduced‑calorie diet with an approximate 500 kcal/day deficit and consider referral to a registered dietitian for individualized meal planning. [14][18]

Critical Pitfalls to Avoid

• Do not use oral pharmacotherapy as monotherapy; it must be paired with lifestyle modification throughout treatment to meet FDA approval criteria and maximize efficacy.
• Do not continue an ineffective oral agent beyond three months if < 5 % weight loss is observed; instead, switch to an alternative medication or expedite surgical referral. 14
• Do not delay bariatric surgery referral in patients with BMI > 60 kg/m², as medication alone will not achieve sufficient weight loss to meaningfully reduce morbidity and mortality. [17][15]

Medication Review and Adjuncts

• Review the patient’s current medication list for weight‑promoting agents (e.g., certain antipsychotics, tricyclic antidepressants, gabapentin, insulin, corticosteroids) and consider alternatives when feasible. 14
• If weight‑promoting drugs cannot be discontinued, adding metformin (≈ 1000 mg daily) or topiramate (≈ 100 mg daily) may help mitigate weight gain. 14

Insurance Appeal Strategy

• When appealing the denial of injectable GLP‑1 agonists, document that the patient’s BMI 62.8 meets the ≥ 30 kg/m² eligibility criterion for anti‑obesity medication. 14

Long‑Term Management Plan

• Bariatric surgery remains the definitive, long‑term solution for severe obesity and should be pursued as the primary therapeutic goal. 15
• Oral pharmacotherapy serves as a bridge while awaiting surgery or for patients who decline operative intervention. 15
• Ongoing, lifelong management is required because weight regain commonly occurs after discontinuation of medication. 14

Pharmacologic Management of Obesity in Adults > 50 Years in Asian Countries

1. Indications for Initiating Weight‑Loss Pharmacotherapy

• Pharmacotherapy should be added to continued lifestyle modification for adults > 50 years with BMI ≥ 25 kg/m² and at least one obesity‑related complication (e.g., hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, obstructive sleep apnea) after failure of a supervised lifestyle program [19][20].
• Initiation is recommended when a patient has not achieved ≥ 5 % weight loss after ≥ 6 months of supervised lifestyle intervention [19][21].
• Pharmacotherapy is also indicated for patients requiring more rapid weight loss because of poorly controlled diabetes or cardiovascular disease, for those experiencing weight regain despite ongoing behavioral therapy, or when greater weight loss is needed to manage obesity‑related complications [19][20]21.

2. BMI and Waist‑Circumference Thresholds Specific to Asian Populations

• Asian adults develop obesity‑related complications at BMI values 2–3 kg/m² lower than Caucasian counterparts; consequently, most South and Southeast Asian guidelines define obesity as BMI ≥ 25 kg/m² (versus ≥ 30 kg/m² in Western guidelines) [22][19].
• For pharmacotherapy eligibility, the BMI threshold is ≥ 25 kg/m² plus at least one obesity‑related comorbidity [19][20].
• Elevated cardiometabolic risk waist‑circumference cut‑offs are ≥ 90 cm for men and ≥ 80 cm for women 22.

3. First‑Line Pharmacologic Options and Expected Efficacy

• Emerging agents (limited availability): Semaglutide 2.4 mg (15 %–20 % loss), Tirzepatide (15 %–21 % loss over 72 weeks) 23; Phentermine‑topiramate ER (avoid in cardiovascular disease) 21.

4. Medication Selection According to Comorbidities & Contraindications

• Type 2 diabetes present – prioritize GLP‑1 receptor agonists (liraglutide or semaglutide if accessible) for dual glycemic and weight benefits 21.
• Cardiovascular disease or uncontrolled hypertension – avoid sympathomimetic agents (phentermine, phentermine‑topiramate); select orlistat, liraglutide, or naltrexone‑bupropion 21.
• Renal or hepatic impairment – adjust dosing and consider agents with minimal renal/hepatic clearance; monitor organ function 21.

5. Monitoring, Treatment Duration, and Discontinuation Criteria

• Initial assessment – evaluate weight, blood pressure, heart rate, and adverse effects monthly for the first 3 months.
• Early discontinuation – stop the medication if < 5 % weight loss is achieved after 12 weeks at the maximum tolerated dose, as this predicts poor long‑term response [19][21].
• Long‑term follow‑up – reassess at least every 3 months; continued therapy is usually required to maintain weight loss and prevent regain [19][21].
• Weight regain after stopping medication is common, supporting the need for indefinite or long‑term treatment in most patients [19][21].

6. Special Considerations for BMI 25–26.9 kg/m²

• Pharmacotherapy may be considered on an individual basis when obesity‑related complications are present, especially if visceral adiposity (elevated waist circumference) and multiple metabolic abnormalities exist [19][22].
• Decision should be made by clinicians experienced in obesity medicine with close monitoring 19.

7. Integration with Lifestyle Modification

• All pharmacologic regimens must be combined with a reduced‑calorie diet (≈ 500 kcal/day deficit) and ≥ 150 minutes/week of moderate‑intensity physical activity [19][20].
• Ongoing behavioral support (dietitians, exercise physiologists, therapists) is essential to maximize efficacy and minimize weight regain [19][20].

8. Indications for Bariatric Surgery in This Population

• Consider surgery when BMI ≥ 32.5 kg/m² (Asian‑specific threshold) with obesity‑related complications despite optimal medical therapy 19.
• Also consider surgery for BMI ≥ 37.5 kg/m² regardless of complications 19.
• Surgery yields 25 %–30 % weight loss at 12 months and superior long‑term outcomes, including reduced cardiovascular mortality, compared with pharmacotherapy alone 23.